Activation of T cells in tumor-bearing mice.
Subcutaneous transplantation of the syngeneic P815 mastocytoma in DBA/2J mice induced an activation of splenic T cells which resulted in a hyperresponsiveness of the tumor-bearing animal to the unrelated antigens pneumococcal polysaccharide (Pn) and sheep red blood cells (SRBC). These tumor-activated T cells appeared to increase the plaque-forming cell (PFC) potential of suboptimal numbers of spleen cells, caused normal spleen cells to express increased numbers of PFC, and produced lymphokine(s) which also increased PFC responses of normal splenocytes. The tumor-activated T cells responsible for stimulating normal splenocytes in an in vitro antibody response were shown to be Ly+2- cells. The activity of the tumor-activated T-cell supernatants was not genetically restricted and required additional Ly1 T cells in order to induce rigorously clean B cells to produce antibody. The T cells capable of stimulating non-specific antibody responses were also capable of slowing tumor growth when injected with tumor cells in normal recipient mice. These results suggest that T cells activated by tumor antigens release immunostimulatory lymphokines and, at the same time, are capable of leading to inhibition of tumor growth.
D000818:Animals; D000921:Antibody-Producing Cells / Q000276:immunology; D000950:Antigens, Ly / Q000276:immunology; D001798:Blood Proteins / Q000502:physiology; D002471:Cell Transformation, Neoplastic / Q000473:pathology; D006462:Hemolytic Plaque Technique; D008213:Lymphocyte Activation; D008297:Male; D012515:Mast-Cell Sarcoma / Q000276:immunology* / Q000401:mortality; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009374:Neoplasms, Experimental / Q000276:immunology / Q000401:mortality; D013154:Spleen / Q000166:cytology; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology* / Q000378:metabolism
D000950:Antigens, Ly; D001798:Blood Proteins; C011850:immunoenhancing factor